Alembic Pharmaceuticals
NSE: APLLTD · ISIN INE901L01018 · Healthcare
₹1,022.10+12.10 (+1.20%)
Monday 9 November, 12:18 IST. Delayed. Source: Yahoo Finance.
Price chart
₹1,022.10 +12.10 (+1.20%) today
The day
- Previous close
- ₹1,010.00
- Open
- ₹1,018.05
- Day high
- ₹1,055.70
- Day low
- ₹1,006.30
Listed on NSE since 20 September 2011.
Key numbers
- Market value
- ₹19,853 Cr
- P/E (trailing)
- 23.53
- EPS (trailing)
- ₹42.93
- Price to book
- 3.34
- Dividend yield
- 1.19%
- Return on equity
- 14.9%
- Debt to equity
- 0.26
- Profit margin
- 9.9%
- Volume today
- 7.19 L
- Average volume
- 2.83 L
Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.
Revenue and profit
| Year | Revenue | Net profit |
|---|---|---|
| FY23 | ₹5,499.77 Cr | ₹341.99 Cr |
| FY24 | ₹6,112.11 Cr | ₹615.82 Cr |
| FY25 | ₹6,539.71 Cr | ₹583.42 Cr |
| FY26 | ₹7,212.61 Cr | ₹674.77 Cr |
Source: Yahoo Finance, from annual reports. Consolidated where reported.
Quarterly results
| Quarter | Revenue | Net profit | Profit vs year ago |
|---|---|---|---|
| Q2 FY27Jul–Sep 2026 | ₹2,603 Cr | ₹335 Cr | +81.5% |
| Q1 FY27Apr–Jun 2026 | ₹2,150 Cr | ₹173 Cr | +12.1% |
| Q4 FY26Jan–Mar 2026Audited | ₹1,848 Cr | ₹202 Cr | +28.5% |
| Q3 FY26Oct–Dec 2025 | ₹1,876 Cr | ₹133 Cr | – |
| Q2 FY26Jul–Sep 2025 | ₹1,910 Cr | ₹185 Cr | – |
| Q1 FY26Apr–Jun 2025 | ₹1,711 Cr | ₹154 Cr | – |
Source: Alembic Pharmaceuticals’s results filed with NSE, consolidated (the whole group). Net profit is the share of Alembic Pharmaceuticals’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.
Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.
Balance sheet
| As on | September 2026 | March 2026 |
|---|---|---|
| Fixed assets | ₹3,457 Cr | ₹3,477 Cr |
| Investments | ₹116 Cr | ₹113 Cr |
| Inventories | ₹2,654 Cr | ₹2,511 Cr |
| Owed by customers | ₹1,896 Cr | ₹1,466 Cr |
| Cash and equivalents | ₹254 Cr | ₹196 Cr |
| Total assets | ₹9,531 Cr | ₹8,763 Cr |
| Borrowings | ₹1,490 Cr | ₹1,361 Cr |
| Total liabilities | ₹3,594 Cr | ₹3,094 Cr |
| Shareholders’ equity | ₹5,944 Cr | ₹5,675 Cr |
Source: Alembic Pharmaceuticals’s half-yearly statements of assets and liabilities filed with NSE, consolidated. Companies file these every September and March.
About Alembic Pharmaceuticals
Alembic Pharmaceuticals Limited, an integrated pharmaceutical company, develops, manufactures, markets, and sells pharmaceutical products in India and internationally. The company provides products in various therapeutic areas, such as cardiology, orthopaedics, anti-diabetic, ophthalmology, gynaecology, nephrology, gastrology, urology, dermatology, anti-infective, cold and cough, and animal health; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It also exports its products. Alembic Pharmaceuticals Limited was founded in 1907 and is headquartered in Vadodara, India.
- Industry
- Drug Manufacturers - Specialty & Generic
- Based in
- Vadodara
- Employees
- 17,244
Company website · Profile: Yahoo Finance
In the news
All newsNo headlines name Alembic Pharmaceuticals in the last day or two.
Dividends and corporate actions
All companies- Dividend - Rs 12 Per Share
Dividend · ex-date 29 July 2026
- Dividend - Rs 11 Per Share
Dividend · ex-date 29 July 2025
- Dividend - Rs 11 Per Share
Dividend · ex-date 15 July 2024
- Dividend - Rs 8 Per Share
Dividend · ex-date 28 July 2023
- Interim Dividend - Rs 10 Per Share
Dividend · ex-date 17 August 2022 · record date 18 August 2022
- Annual General Meeting/Dividend - Rs 14 Per Share
Dividend · ex-date 19 July 2021
- Interim Dividend - Rs 7 Per Share Special Dividend - Rs 3 Per Share
Dividend · ex-date 16 March 2020 · record date 17 March 2020
- Annual General Meeting/Dividend Rs 5.50/-
Dividend · ex-date 18 July 2019
Source: NSE. Latest first, 8 of 15.
Information only, not investment advice. Prices are delayed.